BioCentury | Oct 15, 2012
Company News
Diamyd Medical, Periphagen Holdings deal
...Periphagen for $1 and a holding of 10% in Periphagen. As part of the deal, Periphagen...
...receive 10% of payments Periphagen may receive from future partners, plus royalties on NTDDS-based drugs. Periphagen...
...NTTDS in Phase II testing for cancer pain. Diamyd Medical AB (SSE:DIAM B), Stockholm, Sweden Periphagen Holdings...
...receive 10% of payments Periphagen may receive from future partners, plus royalties on NTDDS-based drugs. Periphagen...
...NTTDS in Phase II testing for cancer pain. Diamyd Medical AB (SSE:DIAM B), Stockholm, Sweden Periphagen Holdings...